Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05275673 · ClinicalTrials.gov registry record · Phase 2
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Faeth Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT05275673 is a Phase 2 study that was terminated before completion, run by Faeth Therapeutics. The registered enrollment target is 7 participants.
The verdict
NCT05275673, a Phase 2 study, was terminated before completion, sponsored by Faeth Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-defined populations of sqNSCLC. Patients with NFE2L2 (the name for gene encoding the protein called NRF2)-mutated or wild-type sqNSCLC should have disease that has progressed on or after at least two prior systemic therapies for metastatic disease including platinum-doublet chemotherapy and a programmed cell death 1 ligand 1 (PD-L1) inhibitor. The study will evaluate sapanisertib monotherapy in patients with relapsed/refractory sqNSCLC as two separate groups: Group A: NFE2L2-mutated sqNSCLC and Group B: NFE2L2-WT sqNSCLC.
Interventions
- DRUG sapanisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2023-01-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05275673
The ClinicalTrials.gov registry entry for NCT05275673 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Faeth Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sapanisertib is the first listed.
NCT05275673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05275673 about?
NCT05275673 is a clinical study titled "A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer". This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-defined populations of sqNSCLC. Patients with NFE2L2 (the name for gene encoding the protein called NRF2)-mutated or wild-type sqNSCLC should have disease that has progressed on or after at least two prior syste...
What is the current status of trial NCT05275673?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2022-07-21. Estimated completion is 2023-01-24.
What interventions are being tested in trial NCT05275673?
The interventions under investigation include: sapanisertib (DRUG).
Who is sponsoring clinical trial NCT05275673?
This trial is sponsored by Faeth Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.